Radio program

CEO of Annovis Bio appears on Executive Leaders Radio Show

BERWYN, Pa., July 23. 20, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage pharmaceutical platform company treating Alzheimer’s disease (AD), Parkinson’s disease (PD) and other diseases neurodegenerative diseases, today announced that its CEO, Maria Maccecchini, Ph.D., will appear on Executive Leaders Radio, broadcast nationally on Radio America ( on July 26, 2020 at 11 a.m. ET.

Executive Leaders Radio is the leading weekly business radio show in the mid-Atlantic states and broadcast nationally on more than 125 terrestrial and Internet radio stations. Executive Leaders Radio conducts “elite interviews” of prominent CEOs, CFOs and Presidents focusing on “what makes people tick”. The show airing on July 26 features CEOs of life sciences companies and explores the connections between early life experiences and career success.

Dr Maccecchini commented: “It is a pleasure to share the story of Annovis Bio with the audience of Executive Leaders Radio and to share my personal story, which drives my passion for understanding and developing solutions for neurodegeneration. .”

About Anvis Bio

Based in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage pharmaceutical platform company treating neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (MA-DS). We believe we are the only company to develop a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and thereby enhances the nerve cell’s information highway, known as of axonal transport. When this flow of information is impaired, the nerve cell becomes ill and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing phase 2a study in patients with AD and plan to start a second phase 2a study in patients with PD and AD. For more information about Annovis, please visit the company’s website:

Forward-looking statements

The statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this press release can be identified by the use of words such as “anticipate”, “expect”, “believe”, “will”, “may”, “should”, “estimate”. , “project,” “outlook,” “forecast,” or other similar words, and include, but are not limited to, statements regarding the timing, efficacy, and expected results of ANVS401 clinical trials and the approval of any additional allowances or patents. Forward-looking statements are based on the current expectations of Annovis Bio, Inc. and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. In addition, certain forward-looking statements are based on assumptions about future events which may not prove to be accurate. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in the Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed with the Securities and Exchange Commission. . The forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no obligation to update such information except as required by applicable law.

Investor Relations:

Dave Gentry, CEO
Companies RedChip Inc.
[email protected]

SOURCE: Annovis Bio Inc.